Study type: In vitro · Status: Verified against declared source

Development and Characterization of Innovative Multidrug Nanoformulation for Cardiac Therapy.

Materials (Basel, Switzerland) · 2023

Study scale: Cell uptake was investigated by incorporating CholEsteryl BODIPY™ in the nanoparticles.

Abstract only: Open source record

Product or molecular entity relationships

SS-31: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Cell uptake was investigated by incorporating CholEsteryl BODIPY™ in the nanoparticles.

Methods

We report herein multidrug nanoparticles based on bioconjugation of CsA and elamipretide with polyisoprenoid derivatives (i.e., squalene or solanesol) (Figure 1).

Scale or participants

Cell uptake was investigated by incorporating CholEsteryl BODIPY™ in the nanoparticles.

Key findings

For several decades, various peptides have been under investigation to prevent ischemia/reperfusion (I/R) injury, including cyclosporin A (CsA) and Elamipretide.

Limitations and uncertainty

For several decades, various peptides have been under investigation to prevent ischemia/reperfusion (I/R) injury, including cyclosporin A (CsA) and Elamipretide.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.